Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Flow cytometric analysis of Jurkat staining with Anti-Human CD5 Antibody, Mouse IgG1 (2C8A7) (Cat. No. FABm032-01) FACS Protocol at 1:20 dilution (5 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL), compared with isotype control antibody. PE signal was used to evaluate the binding activity (QC tested).
1e5 of Mouse Anti-CD5 antibody coupled beads (5.5 μm) were stained with different concentration of Alexa Fluor 488-Labeled Human CD5 Protein, His Tag (Cat. No. CD5-HA2H6) and negative control protein respectively, AF488 signal was used to evaluate the binding activity (QC tested).
Immobilized Alexa Fluor 488-Labeled Human CD5 Protein, Fc Tag (Cat. No. CD5-HA253) at 1 μg/mL (100 μL/well) can bind Mouse Anti-CD5 Antibody, Mouse IgG1 with a linear range of 0.1-4 ng/mL (Routinely tested). Labeling with fluorescent dyes did not affect their activity.
The purity of Rhesus macaque CD5 Protein, His Tag (Cat. No. CD5-R52H3) is more than 90% and the molecular weight of this protein is around 85-105 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CD5 CAR T (CT125B) therapy ( Beijing Boren Hospital) | CD5 CAR T (CT125B); CT125B; CD5 CAR T | Phase 1 Clinical | Beijing Gao Boren Hospital Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CT-125A | CT-125A; RD-125 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Plasmablastic Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| CD5 CAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details | ||
| MT-101 | MT-101 | Phase 2 Clinical | Myeloid Therapeutics Inc | Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides | Details |
| CD5 CAR-T Therapy(Xuanwu Hospital) | Phase 1 Clinical | Xuanwu Hospital Of Capital Medical University | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
This web search service is supported by Google Inc.
A-Z
